至尊英语阅读资料之健康与卫生专题第1010集.pdfVIP

health articles 1010 [25226]Therapeutic Results of Gleevec in Many Cancer Types Since its first administration on human subjects suffering from chronic myeloid leukemia in 2001, Gleevec proved to be the most efficient drug therapy with the most promising improvements. Its targeted action on cancerous white blood cells produced by the abnormally functioning bone marrow also showed less side-effects comparing to prior used drugs. Gleevec has a small rate of toxicity causing nausea, skin rashes or fluid retention but is far more advantageous than drugs injuring internal organs like heart, kidneys or lungs or attacking normal tissues while killing cancer cells. Since 2001 Gleevec has been successfully used in curing other cancer types as well, due to its targeted action on the abnormal tyrosine kinases sending wrong signals to active cells. At least three other cancerous conditions are known to be caused by genetically modified tyrosine kinases. The gastrointestinal stromal tumor was earlier a very difficult to treat disease; it is caused by a different type of tyrosine kinases than the one responsible for chronic myeloid Leukemia but Gleevec could successfully inhibit it as well. About 60% of the patients with this tumor treated with Gleevec showed remarkable improvement and real benefic effects but doctors must still wait a few years to know how long the effects will last. The chronic myelomonocytic leukemia is another very rare encountered blood disease upon which Gleevec proved to be efficient. Myelomonocytic Leukemia is a particular type of myeloid Leukemia also caused by a genetically modified tyrosine kinases. The third cancerous condition with great improvements after the chemotherapy with Gleevec is the hypereosinophilic Syndrome, another blood cancer with an abnormally high multiplication rate of the eosinophilic blood cells responsible for fighting against parasite-linked diseases and allergies. Eosinohils are a type of white blood c